Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345851 · ClinicalTrials.gov registry record · NA
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
A NA study of Stage IIIB Non-small Cell Lung Cancer and Recurrent Non-small Cell Lung Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT01345851 is a NA study of Stage IIIB Non-small Cell Lung Cancer and Recurrent Non-small Cell Lung Cancer that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 29 participants, below the 47-participant average among 16 other Stage IIIB Non-small Cell Lung Cancer trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01345851, a NA study of Stage IIIB Non-small Cell Lung Cancer and Recurrent Non-small Cell Lung Cancer, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies image-guided hypofractionated radiation therapy (RT) when given together with hypofractionated RT boost and combination chemotherapy in treating patients with stage II-III non-small cell lung cancer (NSCLC) that cannot be removed by surgery. RT uses high energy x-rays to kill tumor cells. Hypofractionated RT may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving RT together with combination chemotherapy may kill more tumor cells and allow doctors to save the part of the body where the cancer started
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION hypofractionated radiation therapy
- RADIATION image-guided radiation therapy
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2011-03-23 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01345851
The ClinicalTrials.gov registry entry for NCT01345851 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 16 other Stage IIIB Non-small Cell Lung Cancer trials with a reported enrollment target (38% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Stage IIIB Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01345851 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01345851 about?
NCT01345851 is a clinical study titled "Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery". This clinical trial studies image-guided hypofractionated radiation therapy (RT) when given together with hypofractionated RT boost and combination chemotherapy in treating patients with stage II-III non-small cell lung cancer (NSCLC) that cannot be removed by surgery. RT uses high energy x-rays to ...
What is the current status of trial NCT01345851?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 29 participants. The study started on 2011-03-23. Estimated completion is 2028-01-31.
What conditions does trial NCT01345851 study?
This clinical trial studies the following conditions: Stage IIIB Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of the Lung.
What interventions are being tested in trial NCT01345851?
The interventions under investigation include: laboratory biomarker analysis (OTHER), carboplatin (DRUG), paclitaxel (DRUG), hypofractionated radiation therapy (RADIATION), image-guided radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01345851?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01345851 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIB Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
COMPLETED · NA
-
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
COMPLETED · Early Phase 1
-
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
COMPLETED · Phase 2
-
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Stage IIIB Non-small Cell Lung Cancer
All registered trials for this condition
Recurrent Non-small Cell Lung Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.